Advancing Nucleic Acid Therapeutics: Scalable Strategies for pDNA, mRNA, and LNP Purification Supported by Rapid At-Line Analytics

Join Rok Sekirnik and Tristan Kovačič, to learn how to enhance yield, reduce impurities, and streamline development through targeted choices in plasmid DNA preparation, in vitro transcription, and lipid nanoparticle (LNP) formulation. Discover advanced chromatographic techniques for LNP purification and characterization to ensure your processes meet regulatory standards.

Watch webinar to:

• Learn how in-line lysis approaches compare with batch methods in maintaining plasmid quality and scalability.
• Explore which factors most strongly drive IVT efficiency and how they can be adjusted to minimize double stranded (dsRNA) formation.
• Understand the dual role of oligo dT in maximizing mRNA recovery and supporting impurity removal.
• Learn about novel chromatographic LNP manufacturing techniques that improve and simplify your process.
• Discover approaches for generating meaningful analytical data to characterize LNP formulations with confidence.

Speakers:

• Rok Sekirnik, Head Process Development mRNA | pDNA, BIA Separations, Inc.
• Tristan Kovačič, Project Manager, Process Analytics Development, BIA Separations, Inc.

Abstract:

Efficient, reproducible production of mRNA-based medicines depends on a well-designed continuum spanning plasmid DNA (pDNA) preparation, in vitro transcription (IVT), and lipid nanoparticle (LNP)formulation. In this session, expert speakers will outline how targeted process choices at each stage can significantly improve yield, reduce impurity burden, and simplify downstream development.

Attendees will discover how lysis strategies influence pDNA recovery, what parameters most directly affect IVT reaction performance, and how capture and polishing steps can maximize mRNA purity. The speakers will highlight chromatographic approaches that enable both purification and characterization of increasingly complex LNP formulations. Collectively, these insights will provide a roadmap for developing nucleic acid processes that are scalable, robust, and aligned with regulatory expectations.